ABCR  Vol.5 No.1 , January 2016
Economic Analysis of Intravenous vs. Subcutaneously Administered Trastuzumab for the Treatment of HER2+ Early Breast Cancer in Malaysia
Abstract: Human epidermal growth factor receptor-2 over expression has been reported in 23% - 37.3% of Malaysian breast cancer patients. Trastuzumab is a recommended adjuvant therapy for patients with early breast cancer. Currently, trastuzumab is administered intravenously but a new subcutaneous formulation could save time and costs. In Malaysia, the Ministry of Health funds most of the costs of secondary care, including cancer treatment. We performed a cost-minimisation analysis from the Ministry of Health and societal perspectives by adapting an excel-based mathematical model. Model inputs comprised of drug, consumables and personnel costs. Data sources were government statistics, price lists, government salary scales and estimated personnel time costs. Doctors, nurses and pharmacists at four hospitals estimated the time to perform necessary tasks following their usual practice. Results showed that subcutaneous trastuzumab could, on average, save an estimated 43.5 minutes of pharmacists’ time and 11.6 minutes and 4.9 minutes of nurses’ time administering loading dose and subsequent doses, respectively. Total cost savings were RM7561 (8.7%) per patient per year, consisting of RM6496 (7.6%) reduction in drug cost and RM1065 (66.2%) reduction in non-drug costs. Similarly, cost savings from the societal perspective were RM7820 per patient per year, comprising RM6496 (7.6%) and RM1325 (63.7%) of drug and non-drug costs savings, respectively. Sensitivity analyses showed that cost savings on subcutaneous formulation ranged from RM3715 to RM11408 to the Ministry of Health. Overall, subcutaneous trastuzumab is estimated to be cost-saving from Ministry of Health and societal perspectives. Other benefits from saving patients’ and carers’ time and convenience could not be taken into account. This study was a first to investigate cost-savings from subcutaneous trastuzumab in a middle-income Asian country and the findings were consistent with findings of earlier studies. Given the favourable impact on time and costs, subcutaneous trastuzumab should be considered a viable option for Malaysian patients.
Cite this paper: Lee, W. , Haron, M. , Yu, K. , Chong, F. , Goh, A. and Azmi, S. (2016) Economic Analysis of Intravenous vs. Subcutaneously Administered Trastuzumab for the Treatment of HER2+ Early Breast Cancer in Malaysia. Advances in Breast Cancer Research, 5, 1-13. doi: 10.4236/abcr.2016.51001.

[1]   Youlden, D.R., Cramb, S.M., Yip, C.H. and Baade, P.D. (2014) Incidence and Mortality of Female Breast Cancer in the Asia-Pacific Region. Cancer Biology & Medicine, 11, 101-115.

[2]   Yip, C.H., Cazap, E., Anderson, B.O., Bright, K.L., Caleffi, M., et al. (2011) Breast Cancer Management in Middle-Resource Countries (MRCs): Consensus Statement from the Breast Health Global Initiative. Breast, 20, S12-S19.

[3]   Bhoo-Pathy, N., Hartman, M., Yip, C.H., Saxena, N., Taib, N.A., et al. (2012) Ethnic Differences in Survival after Breast Cancer in South East Asia. PLoS One, 7, e30995.

[4]   Lim, G.C., Aina, E.N., Cheah, S.K., Ismail, F., Ho, G.F., et al. (2014) Closing the Global Cancer Divide—Performance of Breast Cancer Care Services in a Middle Income Developing Country. BMC Cancer, 14, 212.

[5]   World Health Organization (2010) Country Cooperation Strategy 2009-2013.

[6]   Merican, M.I., Rohaizat, Y. and Haniza, S. (2004) Developing the Malaysian Health System to Meet the Challenges of the Future. Medical Journal of Malaysia, 84-93.

[7]   Das, D. and Win, K. (2011) Breast Cancer—Its Impact on National Resource and Survival. RGMHR, 2.

[8]   Yen, S., Abd Shatar, A. and Hashim, H. (2011) The Socioeconomic Impacts of Breast Cancer on Breast Cancer Patients in Penang. Kajian Malaysia, 29, 111-126.

[9]   Pinto, A.C., Ades, F., de Azambuja, E. and Piccart-Gebhart, M. (2013) Trastuzumab for Patients with HER2 Positive Breast Cancer: Delivery, Duration and Combination Therapies. Breast, 22, S152-S155.

[10]   Perez, E.A., Romond, E.H., Suman, V.J., Jeong, J.H., Davidson, N.E., et al. (2011) Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31. Journal of Clinical Oncology, 29, 3366-3373.

[11]   Liberato, N.L., Marchetti, M. and Barosi, G. (2007) Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Journal of Clinical Oncology, 25, 625-633.

[12]   Kurian, A.W., Thompson, R.N., Gaw, A.F., Arai, S., Ortiz, R., et al. (2007) A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/Neu-Positive Breast Cancer. Journal of Clinical Oncology, 25, 634-641.

[13]   Garrison Jr., L.P., Lubeck, D., Lalla, D., Paton, V., Dueck, A., et al. (2007) Cost-Effectiveness Analysis of Trastuzumab in the Adjuvant Setting for Treatment of HER2-Positive Breast Cancer. Cancer, 110, 489-498.

[14]   de Lima Lopes Jr., G. (2011) Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu-Overexpressing Breast Cancer in Singapore. BMC Cancer, 11, 178.

[15]   Yip, C.H., Bhoo Pathy, N. and Teo, S.H. (2014) A Review of Breast Cancer Research in Malaysia. The Medical Journal of Malaysia, 69, 8-22.

[16]   Ismael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., et al. (2012) Subcutaneous versus Intravenous Administration of (Neo)adjuvant Trastuzumab in Patients with HER2-Positive, Clinical Stage I-III Breast Cancer (HannaH Study): A Phase 3, Open-Label, Multicentre, Randomised Trial. The Lancet Oncology, 13, 869-878.

[17]   Roche (Malaysia). Pack Insert for Malaysia. Herceptin® Trastuzumab.

[18]   Genentech (2014) HERCEPTIN® [Trastuzumab] Prescribing Information.

[19]   Roche (2013) CHMP Recommend EU Approval of Roche’s Subcutaneous Herceptin for HER2 Positive Breast Cancer.

[20]   Pivot, X., Gligorov, J., Muller, V., Curigliano, G., Knoop, A., et al. (2014) Patients’ Preferences for Subcutaneous Trastuzumab versus Conventional Intravenous Infusion for the Adjuvant Treatment of HER2-Positive Early Breast Cancer: Final Analysis of 488 Patients in the International, Randomized, Two-Cohort PrefHer Study. Annals of Oncology, 25, 1979-1987.

[21]   Burcombe, R., Chan, S., Simcock, R., Samanta, K. and Percival, F. (2013) Subcutaneous Trastuzumab (Herceptin®): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer. Advances in Breast Cancer Research, 2, 133-140.

[22]   Samanta, K., Moore, L., Jones, G., Evason, J. and Owen, G. (2012) Potential Time and Cost Savings with Herceptin (trastuzumab) Subcutaneous (SC) Injection versus Herceptin Intravenous (IV) Infusion: Results from Three Different English Patient Settings. ISPOR 15th Annual European Congress, Berlin, 3-7 November 2012.

[23]   Mylonas, C., Kourlaba, G., Fountzilas, G., Skroumpelos, A. and Maniadakis, N. (2014) Cost-Minimization Analysis of Trastuzumab Intravenous versus Trastuzumab Subcutaneous for the Treatment of Patients with HER2+ Early Breast Cancer and Metastatic Breast Cancer in Greece. Value in Health, 17, A640-A641.

[24]   De Cock, E., Semiglazov, V., Lopez-Vivanco, G., Verma, S., Pivot, X., et al. (2013) Time Savings with Trastuzumab Subcutaneous vs. Intravenous Administration: A Time and Motion Study. 13th St. Gallen International Breast Cancer Conference, St. Gallen, 13-16 March 2013.

[25]   Scottish Medicines Consortium (2013) Trastuzumab, 600mg/5mL Solution for Injection (Herceptin®). SMC No. (928/13).

[26]   Ministry of Health Malaysia (2002) Clinical Practice Guidelines: Management of Breast Cancer. MOH/P/PAK/212.10 (GU).

[27]   Ministry of Health Malaysia (2015) Ministry of Health Drug Formulary.

[28]   Goldhirsch, A., Winer, E.P., Coates, A.S., Gelber, R.D., Piccart-Gebhart, M., et al. (2013) Personalizing the Treatment of Women with Early Breast Cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology, 24, 2206-2223.

[29]   Senkus, E., Kyriakides, S., Penault-Llorca, F., Poortmans, P., Thompson, A., et al. (2013) Primary Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 24, vi7-vi23.

[30]   Hooi, L.S., Lim, T.O., Goh, A., Wong, H.S., Tan, C.C., et al. (2005) Economic Evaluation of Centre Haemodialysis and Continuous Ambulatory Peritoneal Dialysis in Ministry of Health Hospitals, Malaysia. Nephrology, 10, 25-32.

[31]   Baboolal, K., McEwan, P., Sondhi, S., Spiewanowski, P., Wechowski, J., et al. (2008) The Cost of Renal Dialysis in a UK Setting—A Multicentre Study. Nephrology Dialysis Transplantation, 23, 1982-1989.

[32]   Leveque, D. (2014) Subcutaneous Administration of Anticancer Agents. Anticancer Research, 34, 1579-1586.

[33]   Jabatan Perkhidmatan Awam (2013) Penambahbaikan Jadual Gaji Minimum—Maksimum Gred 1 Hingga Gred 54 Di Bawah Sistem Saraan Malaysia.

[34]   Department of Statistics Malaysia (2013) Salaries and Wages Survey Report: Malaysia 2012.

[35]   Bank Negara Malaysia (2015) Exchange Rates.

[36]   Agnarsson, S. and Jónsdóttir, H. (2013) Comparison of Costs of Different Methods of Administering Herceptin (Trastuzumab). Institute of Economic Studies, University of Iceland, Reykjavík.